ESR1 and breast cancer: Thereafter, based on accumulated data, a mechanistic rationale is provided, pointing out that ER+ breast cancer is a molecular subtype where stimulation of effector immune cells concomitant with hormone therapy is a valid choice to hormone therapy alone.